According to a story from Boehringer Ingelheim Pharmaceuticals, Inc., the company has recently announced positive results from a phase 3 clinical trial testing the company's drug nintedanib (marketed as Ofev)…
Orencia Orencia (abatacept) is a treatment for juvenile idiopathic arthritis (JIA) that was approved for use in the U.S. for the pediatric patient population in 2008. In Japan, the therapy…
According to a story from Global Genes, the drug developer Viela Bio recently issued a presentation of the results from a clinical trial that tested the company's investigational product candidate…
Short Bowel Syndrome Short bowel syndrome (SBS) is a rare condition which occurs when patients have a large portion of their intestine removed. The surgery which leads to this diagnosis…
According to a story from Global Genes, the drug developer Viela Bio recently issued a presentation of the results from a clinical trial that tested the company's investigational product candidate…
-100x150.jpg)
Pharmaceutical companies have spent billions of dollars on Alzheimer’s research. The target has been the toxic protein, amyloid-beta. According to a recent article in NPR News, this theory was…
Three stories of courage are highlighted in Orlando Family Magazine’s annual tribute to the medical community. The first example relates to a mother, Eva, for her courage in opting…
-150x150.png)
It has been less than two years since Cytokinetics’ previous ALS muscle drug, tirasemtiv, failed to meet its endpoint in a Phase III trial to treat ALS. (That was after…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
